

Special Issue

Vaccine Adjuvants for Infectious Diseases

Message from the Guest Editors

Due to their lower immunogenicity when compared to whole pathogen vaccines, adjuvants are a crucial component in the creation of vaccines, particularly for inactivated and subunit-based vaccines. Although adjuvants come in a vast range of structural variations, they all serve the same purpose in vaccine constructs: to strengthen and/or extend the immune response. However, the possibility of negative consequences from the use of adjuvants must be recognized and properly managed. The sort of immunological response required for a specific vaccine should be taken into consideration when choosing an adjuvant because they have various mechanisms of action. As a result, thorough preclinical and clinical research is crucial for adjuvant development. Overall, the use of adjuvants increases opportunities for developing vaccines, and the significance of immune stimulants promotes the creation of new and improved adjuvants. Therefore we would like to encourage the submission of recent findings (original research articles and reviews) about the potential benefits of various adjuvant types, their characteristics, and the processes by which they work in different vaccines for this Special Issue.

Guest Editors

Dr. Morteza Abkar

Department of Genetics, Faculty of Biological Sciences and Technology, Shahid Ashrafi Esfahani University, Isfahan, Iran

Dr. Mahdi Fasihi Ramandi

Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

Deadline for manuscript submissions

closed (20 August 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/155824

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).